| Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates |
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to earnings of $0.68 per share a year ago. |
zacks.com |
2025-05-08 13:20:55 |
Czytaj oryginał (ang.) |
| Entrada Therapeutics Reports First Quarter 2025 Financial Results |
– Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – – Company remains on track to initiate ELEVATE-44-201 and ELEVATE-45-201 in Q2 and Q3 2025, respectively – – Cash runway expected into Q2 2027 with $383 million in cash, cash equivalents and marketable securities as of March 31, 2025 – BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the first quarter ended March 31, 2025, and highlighted recent business updates. “We are excited to announce the first European Union regulatory clearance within our Duchenne franchise, with the authorization to initiate the ELEVATE-44-201 patient study across multiple countries. |
globenewswire.com |
2025-05-08 11:00:00 |
Czytaj oryginał (ang.) |
| Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for |
Entrada Therapeutics (TRDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-29 15:05:47 |
Czytaj oryginał (ang.) |
| Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping |
– Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing – – ELEVATE-45 is the second of three novel exon skipping Duchenne programs the Company expects to progress into global clinical development in 2025 – BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced it has received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee to initiate ELEVATE-45-201. ELEVATE-45-201 is a Phase 1/2 multiple ascending dose (MAD) clinical study to evaluate Entrada's investigational medicinal product ENTR-601-45 for the potential treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation in the DMD gene amenable to exon 45 skipping. |
globenewswire.com |
2025-03-24 09:00:00 |
Czytaj oryginał (ang.) |
| Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates |
Entrada Therapeutics, Inc. (TRDA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.66 per share. This compares to loss of $0.29 per share a year ago. |
zacks.com |
2025-02-27 11:25:36 |
Czytaj oryginał (ang.) |
| Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results |
– Received FDA authorization to initiate ELEVATE-44-102 in the U.S. – – Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. – – Submitted regulatory filings to support global clinical studies for ENTR-601-44 in the EU, and ENTR-601-45 in the U.K. and EU – – Cash runway expected into Q2 2027 with $420 million in cash, cash equivalents and marketable securities as of December 31, 2024 – BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the fourth quarter and full year ended December 31, 2024 and highlighted recent business updates. “We are thrilled to begin 2025 with significant momentum. |
globenewswire.com |
2025-02-27 09:00:00 |
Czytaj oryginał (ang.) |
| Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 |
– Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-44-201 – – Expands global ELEVATE-44 clinical program to include pediatric, adult, ambulatory and non-ambulatory patients with Duchenne muscular dystrophy – BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the United States Food and Drug Administration (FDA) has lifted the clinical hold on ENTR-601-44 and provided authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose (MAD) clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (DMD) in adult patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping. The global ELEVATE-44 program, which includes the ELEVATE-44-102 study in the U.S. and ELEVATE-44-201 outside of the U.S., will cover a broad population of patients with DMD and support evaluation of ENTR-601-44 in patients with both early and advanced disease. |
globenewswire.com |
2025-02-24 09:00:00 |
Czytaj oryginał (ang.) |
| Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside |
Entrada Therapeutics addresses intracellular drug delivery challenges with its Endosomal Escape Vehicle platform, positioning itself uniquely in the biotech sector. Strong financials with $449.3 million in reserves and strategic partnerships extend Entrada's runway into 2027, reducing near-term financing risks. ENTR-601-44, targeting Duchenne muscular dystrophy, is entering critical trials, with potential to validate the platform and drive significant market share. |
seekingalpha.com |
2025-02-19 13:31:37 |
Czytaj oryginał (ang.) |
| Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy |
– Company on track to initiate ELEVATE-44-201 in Q2 2025 – – ENTR-601-44 regulatory filings submitted in additional geographies including the U.S. and EU, with regulatory discussions ongoing – BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced it had received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee for its Clinical Trial of an Investigational Medicinal Product to initiate ELEVATE-44-201, a Phase 1/2 multiple ascending dose (MAD) clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping. “The clearance by the MHRA marks a new phase in Entrada's growth and, most importantly, moves us closer to realizing our commitment to families living with Duchenne muscular dystrophy,” said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics. |
globenewswire.com |
2025-02-03 09:00:00 |
Czytaj oryginał (ang.) |
| Azenta Announces the Election of Dipal Doshi to its Board of Directors |
BURLINGTON, Mass. , Jan. 30, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA) and a recognized leader in the biotechnology and pharmaceutical industries, has been elected to its Board of Directors at its Annual Meeting of Stockholders held earlier today. |
prnewswire.com |
2025-01-30 18:05:00 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for December 30th |
CCRD, TRDA and NRXP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 30, 2024. |
zacks.com |
2024-12-30 13:01:10 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for December 30th |
CCRD, APPN, USNA, TRDA and NRXP have been added to the Zacks Rank #1 (Strong Buy) List on December 30, 2024. |
zacks.com |
2024-12-30 09:21:27 |
Czytaj oryginał (ang.) |
| Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will present at the 43rd Annual J.P. |
globenewswire.com |
2024-12-18 09:00:00 |
Czytaj oryginał (ang.) |
| Recent Price Trend in Entrada Therapeutics (TRDA) is Your Friend, Here's Why |
Entrada Therapeutics (TRDA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. |
zacks.com |
2024-12-11 11:51:11 |
Czytaj oryginał (ang.) |
| Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why |
Entrada Therapeutics (TRDA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. |
zacks.com |
2024-11-25 11:52:08 |
Czytaj oryginał (ang.) |
| Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates |
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to earnings of $1.02 per share a year ago. |
zacks.com |
2024-11-05 11:16:13 |
Czytaj oryginał (ang.) |
| Here's Why Momentum in Entrada Therapeutics (TRDA) Should Keep going |
Entrada Therapeutics (TRDA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. |
zacks.com |
2024-10-31 11:50:18 |
Czytaj oryginał (ang.) |
| Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society |
– Additional positive data from the Company's completed Phase 1 clinical trial evaluating ENTR-601-44 reinforces its safety profile and supports the planned Q4 2024 global regulatory filings for a Phase 2 clinical trial – – Preclinical data presented for the first time, showing exon skipping and dystrophin production for ENTR-601-45, supports the planned Q4 2024 regulatory filings for a global direct-to-patient Phase 2 clinical trial – BOSTON, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. Today the Company announced the presentation of clinical and preclinical data in support of its expanding Duchenne clinical franchise at the 29th Annual Congress of the World Muscle Society in Prague, Czechia from October 8-12, 2024. |
globenewswire.com |
2024-10-09 11:00:00 |
Czytaj oryginał (ang.) |
| Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development |
BOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines. Today, the Company announced that Natarajan Sethuraman, PhD, currently its Chief Scientific Officer, has been promoted to President of Research and Development, effective immediately. |
globenewswire.com |
2024-09-24 11:00:00 |
Czytaj oryginał (ang.) |
| āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors |
BRISBANE, Calif.--(BUSINESS WIRE)--āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced the appointment of Dipal Doshi to its Board of Directors. Mr. Doshi currently serves as Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA). “Dipal is a seasoned leader with significant experience setting strategy and driving the operational and commercial growth of biopharmaceutical. |
businesswire.com |
2024-09-17 12:30:00 |
Czytaj oryginał (ang.) |
| Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program |
- Second annual DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to achieve greater equality for those living with Duchenne - - Announced in celebration of World Duchenne Awareness Day, grants are designed to fund efforts advancing diversity, equity, inclusion and accessibility within the Duchenne community - BOSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. |
globenewswire.com |
2024-09-06 11:00:00 |
Czytaj oryginał (ang.) |
| Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates |
Entrada Therapeutics, Inc. (TRDA) came out with quarterly earnings of $1.55 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to loss of $0.78 per share a year ago. |
zacks.com |
2024-08-13 13:20:37 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 25.73% Upside in Entrada Therapeutics (TRDA): Can the Stock Really Move This High? |
The mean of analysts' price targets for Entrada Therapeutics (TRDA) points to a 25.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-07-25 14:56:06 |
Czytaj oryginał (ang.) |
| Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last? |
Entrada Therapeutics (TRDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. |
zacks.com |
2024-07-12 14:36:36 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for July 9th |
CVNA, AL and TRDA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 9, 2024. |
zacks.com |
2024-07-09 15:16:10 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for July 9th |
CVNA, TRDA, BMBL, APEI and AL have been added to the Zacks Rank #1 (Strong Buy) List on July 9, 2024. |
zacks.com |
2024-07-09 12:35:59 |
Czytaj oryginał (ang.) |
| Entrada Therapeutics Announces $100 Million Registered Direct Offering |
– The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm – – The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm – |
globenewswire.com |
2024-06-24 11:15:00 |
Czytaj oryginał (ang.) |
| Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy |
– ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs, ECGs, physical exams or laboratory assessments – |
globenewswire.com |
2024-06-24 10:00:00 |
Czytaj oryginał (ang.) |
| Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference |
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL. The fireside chat will be held on Monday, June 10, 2024, at 4:00 p.m. Eastern Time. |
globenewswire.com |
2024-06-03 11:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet |
The average of price targets set by Wall Street analysts indicates a potential upside of 37.1% in Entrada Therapeutics (TRDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-05-21 14:56:06 |
Czytaj oryginał (ang.) |